{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:10:59Z","timestamp":1768029059037,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Dept. of Science & Technology (DST), Govt. of India","doi-asserted-by":"publisher","award":["SR\/FST\/CSI-194\/2008"],"award-info":[{"award-number":["SR\/FST\/CSI-194\/2008"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"UGC","doi-asserted-by":"publisher","award":["F1-17.1\/2013-14\/MANF-2013\/14-MUS-ASS-20162"],"award-info":[{"award-number":["F1-17.1\/2013-14\/MANF-2013\/14-MUS-ASS-20162"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.cbi.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T02:55:33Z","timestamp":1455936933000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Human serum albumin reduces the potency of acetylcholinesterase inhibitor based drugs for Alzheimer's disease"],"prefix":"10.1016","volume":"249","author":[{"given":"Mullah Muhaiminul","family":"Islam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Bahadur","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atanu","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kripamoy","family":"Aguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivaprasad","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2016.02.012_bib1","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1039\/c2cp23817a","article-title":"Activity and molecular dynamics relationship within the family of human cholinesterases","volume":"14","author":"Peters","year":"2012","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.cbi.2016.02.012_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.cbi.2016.02.012_bib3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/jpet.102.041616","article-title":"The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development","volume":"306","author":"Terry","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2016.02.012_bib4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","article-title":"Revisiting the cholinergic hypothesis in the development of Alzheimer's disease","volume":"35","author":"Craig","year":"2011","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.cbi.2016.02.012_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","article-title":"Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy","volume":"21","author":"Wilkinson","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.cbi.2016.02.012_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/728983","article-title":"New acetylcholinesterase inhibitors for Alzheimer's disease","volume":"2012","author":"Mehta","year":"2012","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.cbi.2016.02.012_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cbi.2006.05.013","article-title":"Ethidium bromide inhibits rat brain acetylcholinesterase activity in\u00a0vitro","volume":"162","author":"Mazzanti","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2016.02.012_bib8","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1021\/bi962547p","article-title":"Bind the same locus on the nicotinic acetylcholine receptor from torpedo californica","volume":"36","author":"Lurtz","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2016.02.012_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/jm049156q","article-title":"Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-\u03b2 aggregation","volume":"48","author":"Bolognesi","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.cbi.2016.02.012_bib10","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1021\/bi300955k","article-title":"Probing the peripheral site of human butyrylcholinesterase","volume":"51","author":"Macdonald","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2016.02.012_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A\u00a0new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2016.02.012_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-3233(08)60640-3","article-title":"Structure of serum albumin","volume":"45","author":"Carter","year":"1994","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.cbi.2016.02.012_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2133\/dmpk.24.342","article-title":"Lessons from the crystallographic analysis of small molecule binding to human serum albumin","volume":"24","author":"Curry","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.cbi.2016.02.012_bib14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0006-2952(02)01074-2","article-title":"Predicting plasma protein binding of drugs: a new approach","volume":"64","author":"Kratochwil","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2016.02.012_bib15","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.3390\/ijms15033580","article-title":"Interactive association of drugs binding to human serum albumin","volume":"15","author":"Yang","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2016.02.012_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/clinchem\/31.1.60","article-title":"Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid","volume":"31","author":"Barr\u00e9","year":"1985","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cbi.2016.02.012_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/156720106776359177","volume":"3","author":"Hartmann","year":"2006","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.cbi.2016.02.012_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/j.2050-0416.1995.tb00843.x","article-title":"The estimation of thiols and disulphides in barley","volume":"101","author":"Pheifer","year":"1995","journal-title":"J.\u00a0Inst. Brew."},{"key":"10.1016\/j.cbi.2016.02.012_bib19","series-title":"Lehinger Principles of Biochemistry","author":"Nelson","year":"2008"},{"key":"10.1016\/j.cbi.2016.02.012_bib20","series-title":"Evaluation of Enzyme Inhibitors in Drugs Discovery, a Guide for Medicinal Chemists and Pharmacologists","author":"Copeland","year":"2013"},{"key":"10.1016\/j.cbi.2016.02.012_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1208\/s12248-013-9554-7","article-title":"Use of different parameters and equations for calculation of IC50 values in efflux assays: potential sources of variability in IC50 determination","volume":"16","author":"Volpe","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.cbi.2016.02.012_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P","article-title":"Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.cbi.2016.02.012_bib23","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity","volume":"16","author":"Morris","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.cbi.2016.02.012_bib24","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand-protein interaction diagrams for drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.cbi.2016.02.012_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14656566.1.1.121","article-title":"The pharmacology of donepezil: a new treatment for Alzheimer's disease","volume":"1","author":"Wilkinson","year":"1999","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.cbi.2016.02.012_bib26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0006-2952(90)90495-7","article-title":"Pharmacological significance of acetylcholinesterase inhibition by tetrahydroaminoacridine","volume":"40","author":"Marquis","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2016.02.012_bib27","first-page":"223","article-title":"Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers","volume":"31","author":"Mihara","year":"1993","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cbi.2016.02.012_bib28","first-page":"S125","volume":"13","author":"Rogers","year":"1992","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cbi.2016.02.012_bib29","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1517\/13543784.6.10.1527","article-title":"Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease","volume":"6","author":"Heydorn","year":"1997","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.cbi.2016.02.012_bib30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF03324877","article-title":"Serum albumin level interferes with the effect of donepezil in Alzheimer's disease","volume":"20","author":"Rozzini","year":"2008","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.cbi.2016.02.012_bib31","series-title":"Tietz Textbook of Clinical Chemistry","author":"Burtis","year":"1999"},{"key":"10.1016\/j.cbi.2016.02.012_bib32","first-page":"149","article-title":"Comparison of laboratory findings in patients with glomerulonephritis classified according to histopathologic diagnosis","volume":"105","author":"Kirac","year":"2014","journal-title":"Minerva Med."},{"issue":"4","key":"10.1016\/j.cbi.2016.02.012_bib33","first-page":"1","article-title":"Specific antioxidant properties of human serum albumin","volume":"3","author":"Taverna","year":"2013","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.cbi.2016.02.012_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/emboj\/cdg005","article-title":"Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site","volume":"22","author":"Bourne","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.cbi.2016.02.012_bib35","doi-asserted-by":"crossref","first-page":"21530","DOI":"10.1074\/jbc.M112.372961","article-title":"Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands","volume":"287","author":"Finn","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cbi.2016.02.012_bib36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11095-010-0116-8","article-title":"The molecular chaperone \u03b1-crystallin as an excipient in an insulin formulation","volume":"27","author":"Rasmussen","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cbi.2016.02.012_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00002093-200010000-00006","article-title":"RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?","volume":"14","author":"Sramek","year":"2000","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.cbi.2016.02.012_bib38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2016.02.012_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","article-title":"Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex","volume":"48","author":"Kuhl","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cbi.2016.02.012_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00004714-200212000-00012","article-title":"Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease","volume":"22","author":"Kaasinen","year":"2002","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2016.02.012_bib41","first-page":"11","article-title":"Progressive cholinergic decline in Alzheimer's disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology","volume":"7","author":"Sabbagh","year":"2011","journal-title":"BMC Neurol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279716300485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279716300485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:38:52Z","timestamp":1757857132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279716300485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":41,"alternative-id":["S0009279716300485"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2016.02.012","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human serum albumin reduces the potency of acetylcholinesterase inhibitor based drugs for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}